Next Article in Journal / Special Issue
The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer’s Disease
Previous Article in Journal
On the Rate of Synthesis of Individual Proteins within and between Different Striated Muscles of the Rat
Article Menu

Export Article

Open AccessReview
Proteomes 2016, 4(1), 13; doi:10.3390/proteomes4010013

Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms

The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA
Author to whom correspondence should be addressed.
Academic Editors: Edwin Lasonder and Jacek R. Wisniewski
Received: 5 January 2016 / Revised: 10 March 2016 / Accepted: 14 March 2016 / Published: 17 March 2016
(This article belongs to the Special Issue Clinical Proteomics)
View Full-Text   |   Download PDF [1230 KB, uploaded 17 March 2016]   |  


Proteins can exist as multiple proteoforms in vivo, as a result of alternative splicing and single-nucleotide polymorphisms (SNPs), as well as posttranslational processing. To address their clinical significance in a context of diagnostic information, proteoforms require a more in-depth analysis. Mass spectrometric immunoassays (MSIA) have been devised for studying structural diversity in human proteins. MSIA enables protein profiling in a simple and high-throughput manner, by combining the selectivity of targeted immunoassays, with the specificity of mass spectrometric detection. MSIA has been used for qualitative and quantitative analysis of single and multiple proteoforms, distinguishing between normal fluctuations and changes related to clinical conditions. This mini review offers an overview of the development and application of mass spectrometric immunoassays for clinical and population proteomics studies. Provided are examples of some recent developments, and also discussed are the trends and challenges in mass spectrometry-based immunoassays for the next-phase of clinical applications. View Full-Text
Keywords: biomarkers; immunoaffinity; mass spectrometry; posttranslational modifications; top-down analysis biomarkers; immunoaffinity; mass spectrometry; posttranslational modifications; top-down analysis

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Trenchevska, O.; Nelson, R.W.; Nedelkov, D. Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms. Proteomes 2016, 4, 13.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Proteomes EISSN 2227-7382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top